BIIB

Biogen Inc.

Healthcare
188.83 -3.40 -1.77% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 27.88B
EV —
Shares Out 147.64M
Revenue (ttm) 9.94B
Net Income 1.37B
Beta —
P/E 20.26
Forward P/E —
EPS (ttm) $9.30
P/S 2.80
P/B 1.49
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 4.65%
ROE 7.56%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 13.81%
Debt/Eq 0.69
LT Debt/Eq 25.21%
Quick Ratio —
Current Ratio 3.06
Book/sh 126.71
Cash/sh —
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -2.36%
SMA50 0.95%
SMA200 10.36%
Volume 599,509
Avg Volume 1.21M
Rel Volume —
Perf Week -3.66%
Perf Month -0.16%
Perf Quarter 0.40%
Perf Half Y 4.15%
Perf YTD 7.30%
Perf Year 44.85%
Perf 3Y -37.50%
Perf 5Y -34.01%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Biogen Inc. is a global biotechnology company that discovers, develops, manufactures and delivers therapies for patients worldwide. The Company operates through two reportable segments: Neurology and Immunology and Rare Disease. The Neurology segment includes multiple sclerosis (MS) therapies and other neurological products. The Immunology and Rare Disease segment includes therapies for various autoimmune conditions and rare diseases. The Company's product portfolio includes: SPINRAZA for spinal muscular atrophy, SKYCLARYS and QALSODY for rare diseases, ZURZUVAE for depression, VUMERITY and TECFIDERA for MS, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA for MS, and LEQEMBI for Alzheimer's disease (through a collaboration). OCREVUS is a key immunology product. The Company also maintains biosimilar products and engages in contract manufacturing and royalty arrangements. Biogen actively advances a clinical pipeline with programs in neurology, immunology, and rare disease, including Phase 3 trials for multiple candidates. The Company has made strategic acquisitions and collaborations to expand its portfolio, including Reata Pharmaceuticals, Human Immunology Biosciences, and partnerships with organizations like Stoke Therapeutics, City Therapeutics, Eisai, and Ionis Pharmaceuticals for co-development and commercialization of various therapies.

Name
Biogen Inc.
Industry
Biotechnology
CEO
Christopher A. Viehbacher · President and Chief Executive Officer
Employees
7,400 as of 2025-12-31
IPO Date
2014-05-20
Phone
6176792000
Address
225 Binney Street, Cambridge, MA 02142
Website
http://www.biogenidec.com

Key Executives

Name Title FY Pay
Stephen A. Sherwin Director —
Eric K. Rowinsky Director —
William A. Hawkins Director —
Maria C. Freire Chair of the Board —
Christopher A. Viehbacher President and Chief Executive Officer —

Latest News